Literature DB >> 1437510

New developments in the pharmacotherapy of inflammatory bowel disease.

J W Harting1.   

Abstract

In this article the clinical features and aetiology of inflammatory bowel diseases are described and current pharmacotherapeutic possibilities are explored. Also reviewed are recent developments and future prospects for the pharmacotherapy of inflammatory bowel diseases, including aminosalicylates, corticosteroids, immunosuppressants, lipoxygenase inhibitors, fish oil, sucralfate, bismuth compounds, free radical scavengers, (hydroxy)chloroquine, sodium cromoglycate and methotrexate.

Entities:  

Mesh：

Year:  1992        PMID： 1437510     DOI： 10.1007/bf01962550

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN： 0167-6555


  57 in total

1.  Rectal bismuth subsalicylate as therapy for ulcerative colitis.

Authors:  S D Ryder; R J Walker; H Jones; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1990-08       Impact factor: 8.171

2.  The efficacy of tobramycin in the treatment of ulcerative colitis.

Authors:  D A Burke; A T Axon; S A Clayden; M F Dixon; D Johnston; R W Lacey
Journal:  Aliment Pharmacol Ther       Date:  1990-04       Impact factor: 8.171

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 5.  Topical corticosteroids in inflammatory bowel disease.

Authors:  C J Mulder; A A Rondas; E H Wiltink; G N Tytgat
Journal:  Neth J Med       Date:  1989-06       Impact factor: 1.422

6.  Histamine release from gut mast cells from patients with inflammatory bowel diseases.

Authors:  H Nolte; N Spjeldnaes; A Kruse; B Windelborg
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

7.  Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

Authors:  L A Christensen; J Fallingborg; K Abildgaard; B A Jacobsen; G Sanchez; S H Hansen; S Bondesen; E F Hvidberg; S N Rasmussen
Journal:  Aliment Pharmacol Ther       Date:  1990-10       Impact factor: 8.171

Review 8.  5-ASA enema therapy.

Authors:  S B Hanauer
Journal:  Neth J Med       Date:  1989-06       Impact factor: 1.422

9.  The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease.

Authors:  K Teahon; P Smethurst; M Pearson; A J Levi; I Bjarnason
Journal:  Gastroenterology       Date:  1991-07       Impact factor: 22.682

10.  Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content.

Authors:  H W Verspaget; A S Peña; I T Weterman; C B Lamers
Journal:  Gut       Date:  1988-02       Impact factor: 23.059
View more
  3 in total

Review 1.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

Review 3.  Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Francesco Manguso; Raffaele Bennato; Giovanni Lombardi; Elisabetta Riccio; Giuseppe Costantino; Walter Fries
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.